Jonathan Kropski

(iStock)

VUMC study takes closer look at how pulmonary fibrosis unfolds

The research could point to future therapeutic strategies that treat PF patients based on their individual stage of cellular and molecular remodeling.

Alexander Bick, MD, PhD

Two VUMC physician-scientists named to medical honor society

They are among more than 3,500 ASCI members, 48 of whom are current, full-time faculty members of the Vanderbilt University School of Medicine.

Study suggests a new way to treat incurable lung disease

IPF is one of the most common forms of pulmonary fibrosis, an interstitial lung disease characterized by the progressive accumulation of scar tissue (fibrosis) in the epithelial lining of the airways.

(iStock)

Studies to explore molecular drivers of pulmonary diseases

Three grants, totaling over $22 million, were awarded by the National Institutes of Health’s National Heart, Lung, and Blood Institute and will be led by a team of VUMC investigators.

(iStock image)

Cell-specific variations in gene regulation may be key to treating pulmonary fibrosis

An international research team co-led by Vanderbilt University Medical Center has revealed how variations in gene regulation in different cell types drive pulmonary fibrosis, a progressive respiratory disorder characterized by scarring and loss of functional lung tissue.

From left, Nicholas Negretti, PhD, Jonathan Kropski, MD, John Benjamin, MD, MPH, Jennifer Sucre, MD, and Erin Plosa, MD, led the research team that created a single-cell “atlas” of lung development. (photo by Erin O. Smith)

“Atlas” of lung development may aid efforts to heal premature lungs

Researchers at Vanderbilt University Medical Center have constructed a single-cell “atlas” of lung development that tracks multiple cell types over time.